Form 4: SI-BONE CEO Laura Francis Sells Shares to Cover Tax Obligations

SI-BONE CEO Laura Francis sold shares of common stock on May 16 and May 19, 2025, primarily to cover tax withholding obligations related to vesting restricted stock units.

Summary

• Laura Francis, CEO of SI-BONE, Inc., reported the sale of common stock in two transactions on May 16 and May 19, 2025.
• The sales were executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• On May 16, multiple sales occurred at varying prices, resulting in a decrease in direct ownership from 506,511 to 496,399 shares.
• On May 19, an additional 5,412 shares were sold at a weighted average price of $19.487, further reducing direct ownership to 490,987 shares.
• The reported transactions were executed under a 10b5-1 trading plan.
• Francis also indirectly owns 302,958 shares through a trust.
• The filing indicates that Francis directly owns 490,987 shares and indirectly owns 302,958 shares through The David & Laura Joint Rev Tr.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The stock sales are explained as necessary to cover tax obligations, which is a common practice. However, any insider selling can create slight uncertainty among investors.

Positives

• The sales were conducted under a pre-arranged 10b5-1 trading plan, suggesting they were planned and not based on immediate market conditions.
• The explanation provided indicates the sales were to cover tax obligations, which is a common and understandable reason for selling shares.

Negatives

• The CEO selling shares, even for tax purposes, could be perceived negatively by some investors, although the 10b5-1 plan mitigates this concern.

Risks

• While the sales are attributed to tax obligations, continued selling pressure from insiders could negatively impact the stock price.
• Investor sentiment could be affected if there are concerns about insider confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but it indicates ongoing vesting of restricted stock units, which may lead to future sales to cover tax obligations.

Industry Context

Insider trading activity is closely monitored in the medical device industry, as it can provide insights into management's confidence in the company's performance and future prospects. This filing is a routine disclosure of stock sales to cover tax obligations.

Comparison to Industry Standards

• Stock sales by executives to cover tax obligations are common across the industry.
• Comparing the trading activity to peers like Globus Medical or NuVasive would require analyzing their respective insider trading filings.
• The use of a 10b5-1 trading plan is a standard practice to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders if they perceive it as a lack of confidence from the CEO, although the 10b5-1 plan mitigates this.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

SI-BONE, insider trading, Form 4, Laura Francis, stock sale, restricted stock units, tax withholding, 10b5-1 plan, ownership